Compare LINK & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINK | LONA |
|---|---|---|
| Founded | 1984 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.4M | 71.2M |
| IPO Year | 2007 | 2020 |
| Metric | LINK | LONA |
|---|---|---|
| Price | $5.36 | $6.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $8.67 | ★ $10.00 |
| AVG Volume (30 Days) | 19.7K | ★ 41.6K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.83 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,890,000.00 | N/A |
| Revenue This Year | $43.26 | N/A |
| Revenue Next Year | $19.16 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.81 | N/A |
| 52 Week Low | $2.66 | $4.21 |
| 52 Week High | $15.15 | $14.21 |
| Indicator | LINK | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 47.97 | 34.69 |
| Support Level | $3.57 | $4.31 |
| Resistance Level | $6.02 | $8.57 |
| Average True Range (ATR) | 0.35 | 0.65 |
| MACD | -0.08 | -0.11 |
| Stochastic Oscillator | 20.33 | 3.43 |
Interlink Electronics Inc is a provider of sensing technologies and printed electronics solutions that enable Human-Machine Interface (HMI) devices and Internet-of-Things (IoT) applications. Its broad product and technology portfolio spans force and touch sensors, piezoelectric sensors, rugged HMI sensors, wearable and textile-based sensors and electrochemical gas and environmental sensors, along with instruments and fully integrated systems based on its sensor technologies. It serves blue-chip customers and emerging companies across diverse end-use markets, including medical, industrial, automotive, consumer electronics, wearables, environmental monitoring, and specialty applications. It operates in single segment: the design, development, and manufacture of sensor technologies.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.